Drug Patch Approved for Advanced Parkinson's and Restless Leg Syndrome
Neupro thought to stimulate brain receptors governing movement
URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_123679.html(*this news item will not be available after 07/02/2012)
Tuesday, April 3, 2012
The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.
The dopamine agonist skin patch is believed to work by stimulating dopamine receptors within the caudate-putamen, the portion of the brain that regulates movement, the company said.
In clinical testing, observed side effects of Neupro included nausea, vomiting, skin site reactions, dizziness, insomnia and headache.
Neupro contains sodium metabisulfite, which could cause deadly allergic-like reactions in certain susceptible people. Also, the drug should not be used by pregnant women, UCB warned.
HealthDay
Copyright (c) 2012 HealthDay. All rights reserved.
- More Health News on:
- Medicines
- Parkinson's Disease
- Restless Legs
No hay comentarios:
Publicar un comentario